Edition:
India

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

232.70CHF
9:48pm IST
Change (% chg)

CHF-3.30 (-1.40%)
Prev Close
CHF236.00
Open
CHF234.50
Day's High
CHF235.35
Day's Low
CHF232.50
Volume
2,684,417
Avg. Vol
1,731,617
52-wk High
CHF273.00
52-wk Low
CHF226.10

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

Roche's star MS medicine Ocrevus wins EU approval

ZURICH The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.

12 Jan 2018

UPDATE 1-Roche's star MS medicine Ocrevus wins EU approval

ZURICH, Jan 12 The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.

12 Jan 2018

Roche's star MS medicine Ocrevus wins European approval

ZURICH, Jan 12 The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on sale in the United States.

12 Jan 2018

BRIEF-Syapse Enters Strategic Collaboration With Roche To Advance Precision Medicine In Oncology

* SYAPSE ENTERS STRATEGIC COLLABORATION WITH ROCHE TO ADVANCE PRECISION MEDICINE IN ONCOLOGY

09 Jan 2018

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

COPENHAGEN/BRUSSELS Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.

08 Jan 2018

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

COPENHAGEN/BRUSSELS Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.

08 Jan 2018

Novo Nordisk bids $3.1 billion for Belgian biotech group Ablynx

BRUSSELS Denmark's Novo Nordisk , the world's biggest maker of insulin, has made a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx as it seeks to diversify and strengthen its business for treating rare blood disorders.

08 Jan 2018

Swiss stocks - Factors to watch on Jan 8

ZURICH, Jan 8 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 9,582 points on Monday, according to premarket indications by bank Julius Baer .

08 Jan 2018

BRIEF-Roche Holding Ag Says ‍Roche And Ge Enter Partnership To Develop Integrated Digital Diagnostics​

* SAYS ‍ROCHE AND GE ENTER PARTNERSHIP TO DEVELOP INTEGRATED DIGITAL DIAGNOSTICS​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

08 Jan 2018

Europe's biggest private biotech company raises $270 million

LONDON Europe's largest privately held biotech company, Germany-based BioNTech, has raised $270 million to support its work in developing personalized immunotherapies for cancer, ahead of an expected eventual stock market flotation.

04 Jan 2018

Earnings vs. Estimates